The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
Open accessAbstract
BACKGROUND: Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent pericarditis. METHODS: We conducted a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in patients with acute symptoms of recurrent pericarditis (as assessed on a patient-reported scale) and systemic inflammation (as shown by an elevated C-reactive protein [CRP] level). Patients presenting with pericarditis recurrence while receiving standard therapy were enrolled in a 12-week run-in period, during which rilonacept was initiated and background medications were discontinued. Patients who had a clinical response (i.e., met prespecified response criteria) were randomly assigned in a 1:1 ratio to receive continued rilonacept monotherapy or placebo, administered subcutaneously once weekly. The primary efficacy end point, assessed with a Cox proportional-hazards model, was the time to the first pericarditis recurrence. Safety was also assessed. RESULTS: A total of 86 patients with pericarditis pain and an elevated CRP level were enrolled in the run-in period. During the run-in period, the median time to resolution or near-resolution of pain was 5 days, and the median time to normalization of the CRP level was 7 days. A total of 61 patients underwent randomization. During the randomized-withdrawal period, there were too few recurrence events in the rilonacept group to allow for the median time to the first adjudicated recurrence to be calculated; the median time to the first adjudicated recurrence in the placebo group was 8.6 weeks (95% confidence interval [CI], 4.0 to 11.7; hazard ratio in a Cox proportional-hazards model, 0.04; 95% CI, 0.01 to 0.18; P<0.001 by the log-rank test). During this period, 2 of 30 patients (7%) in the rilonacept group had a pericarditis recurrence, as compared with 23 of 31 patients (74%) in the placebo group. In the run-in period, 4 patients had adverse events leading to the discontinuation of rilonacept therapy. The most common adverse events with rilonacept were injection-site reactions and upper respiratory tract infections. CONCLUSIONS: Among patients with recurrent pericarditis, rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo. (Funded by Kiniksa Pharmaceuticals; RHAPSODY ClinicalTrials.gov number, NCT03737110.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC Guidelines for the diagnosis and management of pericardial diseases
Adler, Y., Charron, P., Imazio, M., Badano, L., Barón-Esquivias, G., Bogaert, J., Brucato, A., Gueret, P., Klingel, K., Lionis, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv318 · Cited by 2,634
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
A Randomized Trial of Colchicine for Acute Pericarditis
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Maggiolini, S., Beqaraj, F., Demarie, D., Forno, D., Ferro, S., Maestroni, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208536 · Cited by 611
Self-citationImazio, M., Belli, R., Brucato, A., Cemin, R., Ferrua, S., Beqaraj, F., Demarie, D., Ferro, S., Forno, D., Maestroni, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62709-9 · Cited by 406
Self-citationBrucato, A., Imazio, M., Gattorno, M., Lazaros, G., Maestroni, S., Carraro, M., Finetti, M., Cumetti, D., Carobbio, A., Ruperto, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.15826 · Cited by 401
Self-citationManagement of Acute and Recurrent Pericarditis
Chiabrando, J. G., Bonaventura, A., Vecchié, A., Wohlford, G. F., Mauro, A. G., Jordan, J. H., Grizzard, J. D., Montecucco, F., Berrocal, D. H., Brucato, A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.021 · Cited by 396
Self-citationColchicine for Recurrent Pericarditis (CORP): A Randomized Trial
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Belli, R., Maestroni, S., Trinchero, R., Spodick, D. H., Adler, Y., & on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-7-201110040-00359 · Cited by 389
Self-citationCastarlenas, E., Jensen, M. P., von Baeyer, C. L., & Miró, J. (2017) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000406 · Cited by 311
Picco, P. P., Brisca, G., Traverso, F., Loy, A., Gattorno, M., & Martini, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24174 · Cited by 167
Relapsing pericarditis: Table 1
Soler‐Soler, J., Sagristà-Sauleda, J., & Permanyer-Miralda, G. (2004) · Heart · doi:10.1136/hrt.2003.026120 · Cited by 150
Brucato, A. L., Emmi, G., Cantarini, L., Lenarda, A. D., Gattorno, M., Lopalco, G., Marcolongo, R., Imazio, M., Martini, A., & Prisco, D. (2018) · Internal and Emergency Medicine · doi:10.1007/s11739-018-1842-x · Cited by 71
Self-citationInterleukin-1 blockade for the treatment of pericarditis
Buckley, L. F., Viscusi, M. M., Tassell, B. W. V., & Abbate, A. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx018 · Cited by 69
Self-citationKlein, A. L., Imazio, M., Brucato, A. L., Cremer, P. C., LeWinter, M. M., Abbate, A., Lin, D., Martini, A., Beutler, A. M., Chang, S. Y., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.004 · Cited by 65
Self-citationSigna, S., D’Alessandro, M., Consolini, R., Miniaci, A., Bustaffa, M., Longo, C., Tosca, M. A., Bizzi, M., Caorsi, R., Mendonça, L. O., et al. (2020) · Pediatric Rheumatology · doi:10.1186/s12969-020-00438-5 · Cited by 50
Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases
Emmi, G., Urban, M. L., Imazio, M., Gattorno, M., Maestroni, S., Lopalco, G., Cantarini, L., Prisco, D., & Brucato, A. L. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1007-6 · Cited by 33
Self-citation
Cited by
2025 ESC Guidelines for the management of myocarditis and pericarditis
Schulz-Menger, J., Collini, V., Gröschel, J., Adler, Y., Brucato, A., Christian, V., Ferreira, V. M., Gandjbakhch, E., Heidecker, B., Kerneis, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf192 · Cited by 434
Self-citationThe role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Self-citationThe Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease
Zhang, H., & Dhalla, N. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021082 · Cited by 385
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Self-citationDobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 268
Metadata
- Authors
- Klein, A. L., Imazio, M., Cremer, P., Brucato, A., Abbate, A., Fang, F., Insalaco, A., LeWinter, M., Lewis, B. S., Lin, D., Luis, S. A., Nicholls, S. J., Pano, A., Wheeler, A., & Paolini, J. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-01-07
- Volume
- 384
- Issue
- 1
- Pages
- 31-41
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3104562917
- Cited by
- 358
- References
- 15
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.